Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07039760 · ClinicalTrials.gov registry record · Early Phase 1
Asciminib With or Without Sildenafil for Brain Tumors
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT07039760 is a Early Phase 1 study that has not yet begun recruiting, run by Washington University School of Medicine. The registered enrollment target is 12 participants.
The verdict
NCT07039760, a Early Phase 1 study, has not yet begun recruiting, sponsored by Washington University School of Medicine.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Dissemination of medulloblastoma is an independent risk factor of poor prognosis. Dissemination of medulloblastoma at recurrence is nearly universally fatal. ABL1 and 2 have been recently found to mediate the dissemination of medulloblastoma. Genetically inactivating ABL1 and 2 resulted in decreased leptomeningeal medulloblastoma and improved overall survival (OS) in rodent models. ABL kinases have also been shown to play a role in the malignant properties of glioblastoma. Asciminib is an FDA approved for the treatment of chronic myeloid leukemia and is well tolerated, likely due to its specificity for ABL1 and ABL2. Asciminib is a P-glycoprotein (P-gp) substrate and thus may be susceptible to being pumped out of tumor cells and brain endothelial cells. It is unclear if asciminib can enter the central nervous system (CNS) and brain tumors in adequate concentration to have anti-tumor effects.
Interventions
- DRUG Asciminib
- DRUG Sildenafil
- PROCEDURE Surgical resection or biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-08-31 |
| Est. Completion | 2028-03-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07039760
The ClinicalTrials.gov registry entry for NCT07039760 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Asciminib is the first listed.
NCT07039760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07039760 about?
NCT07039760 is a clinical study titled "Asciminib With or Without Sildenafil for Brain Tumors". Dissemination of medulloblastoma is an independent risk factor of poor prognosis. Dissemination of medulloblastoma at recurrence is nearly universally fatal. ABL1 and 2 have been recently found to mediate the dissemination of medulloblastoma. Genetically inactivating ABL1 and 2 resulted in decreased...
What is the current status of trial NCT07039760?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2026-08-31. Estimated completion is 2028-03-31.
What interventions are being tested in trial NCT07039760?
The interventions under investigation include: Asciminib (DRUG), Sildenafil (DRUG), Surgical resection or biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT07039760?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.